Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Recipient : Jerry Vockley
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-Label Study of ACER-001 in Treatment of Combined D,L-2 Hydroxyglutaric Aciduria
Details : Sodium Phenylbutyrate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of 2-Hydroxyglutaricaciduria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 15, 2025
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Recipient : Jerry Vockley
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arimoclomol Citrate,Miglustat
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : $150.0 million
Deal Type : Agreement
Zevra Sells Rare Disease Review Voucher For $150 Million
Details : Zevra sold it's Rare Pediatric Disease PRV for FDA approved of Miplyffa (arimoclomol). It is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC. C
Product Name : Miplyffa
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 07, 2025
Lead Product(s) : Arimoclomol Citrate,Miglustat
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : $150.0 million
Deal Type : Agreement
Lead Product(s) : Arimoclomol Citrate,Miglustat
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : $150.0 million
Deal Type : Agreement
Zevra to Sell Rare Pediatric Disease Voucher for $150M
Details : Zevra sold it's Rare Pediatric Disease PRV for FDA approved of Miplyffa (arimoclomol). It is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC. C
Product Name : Miplyffa
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 27, 2025
Lead Product(s) : Arimoclomol Citrate,Miglustat
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : $150.0 million
Deal Type : Agreement
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Recipient : Jerry Vockley
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sodium Phenylbutyrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Medium chain acyl CoA dehydrogenase Deficiency.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Recipient : Jerry Vockley
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arimoclomol Citrate,Miglustat
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zevra Launches MIPLYFFA™ in US for Niemann-Pick Disease Type C Treatment
Details : Miplyffa (arimoclomol) is a first in class oral HSF1 activator approved for Niemann-Pick disease type C in combination with miglustat.
Product Name : Miplyffa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 21, 2024
Lead Product(s) : Arimoclomol Citrate,Miglustat
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arimoclomol Citrate,Miglustat
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves First Treatment for Niemann-Pick Disease, Type C
Details : Miplyffa (Arimoclomol) is indicated for use in combination with miglustat for the treatment of Niemann-Pick disease type C in adult and pediatric patients 2 years of age and older.
Product Name : Miplyffa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 20, 2024
Lead Product(s) : Arimoclomol Citrate,Miglustat
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arimoclomol Citrate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Cantor Fitzgerald
Deal Size : Undisclosed
Deal Type : Public Offering
Zevra Therapeutics Announces Proposed Public Offering of Common Stock
Details : The net proceeds from this offering will used to support the pre-commercial launch activities for BRX-345 (arimoclomol) for the treatment of Niemann-Pick Disease Type C.
Product Name : Miplyffa
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 08, 2024
Lead Product(s) : Arimoclomol Citrate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Cantor Fitzgerald
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Arimoclomol Citrate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Advisory Committee Supports Arimoclomol as Effective for Niemann-Pick Disease Type C
Details : BRX-345 (arimoclomol) is a first in class oral HSF1 activator being investigated for Niemann-Pick disease type C. The FDA has accepted the resubmitted NDA and set a PDUFA date of September 21, 2024.
Product Name : Miplyffa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 02, 2024
Lead Product(s) : Arimoclomol Citrate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arimoclomol Citrate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zevra Announces FDA Advisory Committee Meeting for Arimoclomol in Niemann-Pick Disease
Details : BRX-345 (arimoclomol) is a first in class oral HSF1 activator being investigated for Niemann-Pick disease type C. The FDA has accepted the resubmitted NDA and set a PDUFA date of September 21, 2024.
Product Name : Miplyffa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 09, 2024
Lead Product(s) : Arimoclomol Citrate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexmethylphenidate
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zevra Announces Positive Phase 2 Results of KP1077 for Hypersomnia at SLEEP 2024
Details : KP1077 (serdexmethylphenidate) is a prodrug of d-methylphenidate, which acts as dopamine & norepinephrine transporter antagonists. It is being evaluated for the treatment of idiopathic hypersomnia.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 03, 2024
Lead Product(s) : Dexmethylphenidate
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable